Immunology/Immunotherapy

免疫系统既是恶性肿瘤的来源，也是癌症治疗的工具。这个 免疫学/免疫治疗计划(IMM)支持基础和临床研究，以增加 了解和控制(1)对癌症的免疫反应和(2)造血细胞的途径 发育及其失调可用于治疗恶性血液病。IMM计划成员 通过三个科学主题实现这两个方面的目标：(1)发展和优化 抗原导向免疫治疗；(2)抗肿瘤质量的正负调节 豁免权。(3)血液病和恶性血液病的控制。这些主题包括杰出的 基础科学研究，以及开发临床试验的高度协作的翻译倡议 在此研究的基础上。项目联合负责人、博士维克多·恩格尔哈德因其工作而获得国际认可 在肿瘤抗原识别和诱导肿瘤特异性CD8 T细胞反应中的作用。项目联合负责人， 克雷格·斯林格勒夫医学博士通过这两项实验室研究为癌症免疫治疗做出了重大贡献 以及由研究人员主导的临床试验。该计划由27名正式成员和3名准成员组成 来自医学院的六个系。该方案的外部资金总额超过17美元 100万美元，其中包括来自国家癌症研究所(NCI)的400万美元。计划成员制作了293个 癌症相关出版物，其中21%是方案间出版物，19%是方案内出版物 最后一次更新。该计划支持正在进行的研究报告和研讨会，以产生新的 导演和合作；试点资金，以鼓励发展有前途的合作和想法； 和一个免疫监测实验室，以促进临床研究。17名研究人员发起的临床 由方案成员领导的试验，包括HWO ECOG试验和另外三个多中心试验， 从六种癌症组织中招募患者，并评估多肽疫苗、细胞因子和抗体。 这些试验测试了实验室科学产生的假说，也给实验室带来了麻烦 研究细胞过程和分子机制以解释临床发现。本计划 为在了解免疫系统和应用方面取得有限进展奠定了坚实的基础 这一知识有助于提高血液系统恶性肿瘤的免疫治疗和治疗。

The immune system is both a source of malignancies and a tool for cancer therapy. The Immunology/lmmunotherapy Program (IMM) supports basic and clinical research to increase the understanding and control of (1) the immune response to cancer and (2) the ways hematopoiefic cell development and its dysregulation can be used to treat hematologic malignancies. IMM Program members approach this two-faceted goal through three scientific Themes: (1) Development and Opfimizafion of Antigen-Directed Immunotherapeutics; (2) Positive and Negative Regulation of the Quality of Anti-Tumor Immunity. (3) Control of Hematopoiesis and Hematologic Malignancies. These Themes include outstanding basic science investigations, as well as highly collaborative translational initiatives to develop clinical trials based on this research. Program Co-Leader, Victor Engelhard, PhD, is internationally recognized for his work in tumor antigen identificafion and inducfion of tumor-specific CD8 T cell responses. Program Co-leader, Craig Slingluff, MD, has made major contribufions to cancer immunotherapy through both laboratory research and investigator-inifiated clinical trials. The Program consists of 27 Full Members and 3 Associate Members from six departments in the School of Medicine. Total extramural funding for the Program exceeds $17 million, including $4 million from the National Cancer Institute (NCI). Program Members have produced 293 cancer-relevant publications, of which 21% were inter-programmatic and 19% were intra-programmafic since the last renewal. The Program supports research in progress presentations and seminars to engender new direcfions and collaborafions; Pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen investigator-initiated clinical trials led by Program Members, including hwo ECOG trials and three additional multicenter trials, have enrolled patients across six cancer histologies and evaluated pepfide vaccines, cytokines, and antibodies. These trials test hypotheses arising from laboratory science and also bring fissue to the laboratories to invesfigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for confinued advances in both understanding of the immune system and ufilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.